Another week with another set of macro concerns. I was waiting to see if there would be any interesting biotech news but I guess not. There was some late last week but this morning seems driven by macro (your choice between Argentina and/or Hong Kong and/or China trade). I see little on the horizon that […]
DMD Data by Giant Pharma Pfizer Kept Sarepta In the Driver Seat with Superior Drug
Pfizer (PFE) presented its first set of data (n=6) from the mini-dystrophin gene therapy for DMD (PF-06939926) at the PPMD conference on June 28th. Much speculations surrounded Pfizer’s decision to report the dystrophin quantification using mass-spec. Sarepta (SRPT) has used WB-western blot since 2015 during the Eteplirsen FDA approval process. Sarepta has also used it in […]
June 25 Biotech Update
So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its implications. 1. I need to go back and listen the conference call so there might be some additional insight later this week but this deal […]
May 6th Biotech Update
Not the best start to the week for the market with the surprise tariff news hitting the market. I would not be stunned for the effect to be muted given how frequently Chine trade news changes. For all we know progress will be made this afternoon and all will be good again. As such, my […]
Sarepta – LGMD2E Data May Become the Next Inflection Point
Sarepta Therapeutics (SRPT) has a long history with several inflection points through the years. Moving upward from a penny stock back in the days they used to be called AVI Biopharma, through the first inflection point and stepping under the spotlight with first real eteplirsen success, meeting the primary endpoint of increase dystrophin and achieving […]
PSTI – The Future Regenerative Medicine Leader – Trading Under the Radar
• Regenerative medicine company with late-stage studies in 3 indications • Ready to use GMP-certified manufacturing facility for PLX cells • Aging is often associated with debilitating medical conditions, massive unmet needs • Over 617 million people in the world are over 65 years old • Over 70 million people in the U.S. are over […]
Bria-IMT Combination Study with KEYTRUDA®: What the Early Data Show
BriaCell presented some data from the ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab)], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer at SABCS, as well as some additional monotherapy data. While the poster does not provide a lot of data on combination patients (as expected given […]
CEO Interview: Bellus Outlook Post the Positive Ph1 Chronic Cough Study
Back in August I published my deep dive report “Bellus – David vs. Goliath, Can BLU Deliver A Better Chronic Cough Drug Than Merck?” (Link) with a bull thesis stating that Bellus Health (TSX: BLU.TO) (OTC: BLUSF) have a good chance to pass the first true hurdle and achieve positive results from their clinical trial […]
Dave-Trading November 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
Bria-IMT Combination Study with KEYTRUDA®: What to Know and Why
In a previous interview, BriaCell (TSX:BCT.V) (OTCQB:BCTXF) (or the Company)’s President and CEO, Dr. Bill Williams cited as a near-term catalyst data from the Company’s ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab) ], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer. Initiated in October, the study […]
Opinion: No, The Antibiotics Market Is Not Broken
In light of slow drug launches and disappointing sales, there is a growing chorus of voices saying the antibiotics drug market is broken; that the government must step in to save one of our most important resources. With no profits to pursue, it is said, companies will abandon antibiotics, leaving society vulnerable to the spread […]
Bellus – David vs. Goliath Round 2 – Can BLU Expand the Pipeline Following Merck Lead?
Back in August I published my first deep dive report “Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?” (Link) about Bellus Health (BLU.TO) (BLUSF) a biopharmaceutical development company based in Montreal, Canada. Its lead drug candidate is BLU-5937 which is a highly selective P2X3 antagonist that has the […]
APTO – We Came for A Trade and Back for The Long-Term Potential
The First time I met Aptose Biosciences (APTO) was at the Bloom-Burton conference in Toronto back in May 2018 following the request of several Chimera Research Group (CRG) subscribers. They asked me to check out the company’s presentation and try to get more info about the status of the clinical hold and when we might […]
Briacell Interview
Chimera Research Group: What sets Briacell apart from other immuno-oncology approaches? Dr. William V. Williams, President and CEO of Briacell: Briacell is developing a novel cancer immunotherapy based on a cancer cell line called SV-BR-1-GM a.k.a. Bria-IMT™. It was originally taken from a breast cancer patient, and further genetically altered to express GM-CSF, a stimulator […]
SRPT – Again, WMS-2018 Dystrophin Data Beating the Market Expectation
Yesterday 10/04, at 7:00 am ET, Sarepta Therapeutics (SRPT) with Dr. Mendell released the biopsy data from the fourth patient including full 4 patients “Functional Data” from Argentina at #WMS2018 the 23rd International Annual World Muscle Society meeting Link to the full slide deck: https://www.sec.gov/Archives/edgar/data/873303/000119312518292068/d616670dex992.htm The after-hours share price reaction was wild swing, spiking up […]
Dave Trading – September 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
XENE Pipeline Keep Growing – Is XEN007 The Next Surprise?
Last week, Xenon pharmaceuticals (XENE) passed one of the most important tests in the stock market, where the share price closed on Friday at $14.05, above the $14.03 resistance line, despite the news of the $50 million public offering, followed by the news of upsizing the offering to $63 million at $14.00 per share, only […]
XENE – Quick note, Positive TMS Data Presented at The European Congress on Epileptology
Today morning, Xenon Pharmaceutical (XENE) reported positive data from its XEN1101 Phase 1b transcranial magnetic stimulation (TMS) study. (LINK) XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Historical Ezogabine Data XEN1101 […]
Dave Trading – August 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?
BELLUS Health (BLU.TO) (BLUSF) is a biopharmaceutical development company based in Quebec, Canada, its pipeline includes several partnered clinical-stage drug development programs, but the company’s lead drug candidate is BLU-5937 which is a highly selective P2X3 antagonist for chronic cough and has the potential to be a best-in-class therapeutic for chronic cough patients who do […]
